Superparamagnetic iron oxide based MRI contrast agents: Current status of clinical application.

By Yi-Xiang J. Wang. Quantitative Imaging in Medicine and Surgery, 2011

696 citations recorded by the source corpus.

Subfields: Epidemiology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/8b1600b851be9aa9dac62c6bac1517fd60081df7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. N. Desai

In Radiology, Nuclear Medicine and Imaging

1. N. Bertrand
2. N. Desai

Citations in the corpus

• Challenges in Development of Nanoparticle-Based Therapeutics (2012, background): “The complement activation can lead to rapid phagocytosis and clearance by macrophages of the MPS system in the liver and spleen, such as in the cases of superparamagnetic iron oxide nanoparticles Ferumoxtran-10 (Combidex) and ferumoxytol (Feraheme) (79).”
• Iron Oxide Nanoparticles: Diagnostic, Therapeutic and Theranostic Applications (2019, background): “Molecular weight and surface density of PEG coatings are two critical parameters that influence the dispersion stability, cytotoxicity and blood circulation time of iron oxide nanoparticles [71,87].”
• Interactions of nanomaterials and biological systems: implications to personalized nanomedicine (2012, background): “high accuracy during delayed phase imaging [163] and ferocarbotan, which can be administered as a rapid bolus, to produce higher”